Please login to the form below

Not currently logged in
Email:
Password:

Mylan agrees $1.6bn deal to buy Agila injectables unit

Generics firm becomes “top three player” in injectables

Mylan headquarters

Consolidation continues apace in the generics sector, with Mylan agreeing a $1.6bn deal to acquire Strides Arcolab of India's sterile injectables business unit.

The deal for Bangalore-based Agila Specialties boosts Mylan's position in a therapeutic category which has been plagued by shortages in the US and elsewhere, as a result of manufacturing problems and some companies withdrawing from the market.

Mylan's chief executive Heather Bresch said absorbing Agila Specialities will make the company a "top three player" in injectables and double the company's turnover in the category to around $1bn in the first year after the acquisition concludes. The deal is expected to close in the fourth quarter of 2013.

"Agila brings us one of the most diversified, highest-quality and state-of-the-art injectables manufacturing bases in the industry", boosting capacity 50-fold, said Bresch on a conference call yesterday to discuss the deal and Mylan's fourth-quarter results.

The deal follows other large-scale M&A deals in the generics sector in recent months, notably the $5.9bn Watson-Actavis merger, Sandoz ' $1.53bn acquisition of Fougera Pharma and Sun Pharma's $600m transaction to take a majority-stage in Taro Pharma.

For Mylan, the deal follows the acquisitions of Merck KGaA's generics business for $6.7bn in 2008, a $550m deal for Ireland's Bioniche in 2010 and the $33m takeover of an SMS Pharma manufacturing facility in India, as well as an insulin analogue/biosimilar collaboration signed with Biocon earlier this month.

The proposed takeover also boosts its geographic presence, particularly in emerging pharma markets such as Brazil which accounts for a quarter of Agila Specialties' turnover, provides another platform for Mylan's biosimilar aspirations.

The agreement comes as Mylan reported record financial results in 2012, with revenues up 14 per cent to $6.8bn on the back of 600 product launches around the world, and earnings per share 27 per cent higher at $2.59.

28th February 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....